Insights into Cleavage Specificity from the Crystal Structure of Foot-and-Mouth Disease Virus 3C Protease Complexed with a Peptide Substrate. by Zunszain, PA et al.
Journal of Molecular Biology, 395, 357-389 (2010) http://www.ncbi.nlm.nih.gov/pubmed/19883658
Insights into Cleavage Specificity from the Crystal 
Structure of Foot-and-Mouth Disease Virus 3C Protease 
Complexed with a Peptide Substrate
Patricia A. Zunszain1, Stephen R. Knox2, Trevor R. Sweeney1, Jingjie Yang1, Núria 
Roqué-Rosell2, Graham J. Belsham3, Robin J. Leatherbarrow2 and Stephen Curry1*
1Biophysics Section, Blackett 
Laboratory, Imperial College, 
Exhibition Road, London, SW7 
2AZ, UK. 
2Department of Chemistry, 
Imperial College, Exhibition 
Road, London, SW7 2AZ, UK. 
3Technical University of 
Denmark, National Veterinary 
Institute, Lindholm, 4771 
Kalvehave, Denmark.





Picornavirus replication is critically dependent  on the correct processing of 
a polyprotein precursor by the 3C protease at multiple, specific sites with 
related but non-identical sequences. To investigate the structural basis of 
its cleavage specificity, we performed the first  crystallographic structural 
analysis of non-covalent  complexes of a picornavirus 3C protease with 
peptide substrates. The X-ray crystal structure of the foot-and-mouth 
disease virus 3C protease (FMDV 3Cpro), mutated to replace the catalytic 
Cys by Ala, bound to a peptide (APAKQ|LLNFD) corresponding to the 
P5-P5´ region of the VP1-2A cleavage junction in the viral polyprotein 
was determined to 2.5 Å resolution. Comparison with the free enzyme 
reveals significant conformational changes in 3Cpro on substrate binding 
that lead to formation of an extended interface of contact  primarily 
involving the P4-P2´ positions of the peptide. Strikingly, the deep S1´ 
specificity pocket needed to accommodate P1´-Leu only forms when the 
peptide binds. The substrate specificity was investigated using peptide-
cleavage assays to show the impact  of amino acid substitutions within the 
P5-P4´ region of synthetic substrates. The structure of the enzyme-peptide 
complex explains both the marked substrate preferences for particular P4, 
P2 and P1 residue types as well as the relative promiscuity at P3 and on 
the P´ side of scissile bond. Further, crystallographic analysis of the 
complex with a modified VP1-2A peptide (APAKE|LLNFD), containing a 
Gln to Glu substitution, reveals an identical mode of peptide binding and 
explains the ability of FMDV 3Cpro to cleave sequences containing either 
P1-Gln or P1-Glu. Structure-based mutagenesis was used to probe 
interactions within the S1´ specificity pocket and to provide direct 
evidence of the important contribution to proteolytic activity made by Asp 
84 of the Cys-His-Asp catalytic triad. Our results provide a new level of 
detail in our understanding of the structural basis of polyprotein cleavage 
by 3Cpro.
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Introduction 
Foot-and-mouth disease (FMD) is a serious, widespread viral 
disease of cloven-hoofed animals, including important 
agricultural species such as cattle, sheep, pigs and goats1,2. The 
virus spreads rapidly and, although endemic and epidemic 
situations can be controlled using vaccines that are based on 
inactivated virus particles, political and technical difficulties 
with  the maintenance and use of vaccine stocks has stimulated 
the search for alternative means of tackling the disease, such as 
anti-viral drugs3. The development of such treatments will 
demand a detailed knowledge of the molecular basis of viral 
replication. In this paper we focus  on the structural basis  of the 
cleavage activity of FMDV 3Cpro. As a highly conserved viral 
enzyme4, FMDV 3Cpro is a potential drug target.
Foot–and-mouth disease virus (FMDV) is a single-stranded, 
positive sense RNA virus belonging to the picornavirus family 
that also includes human pathogens such  as poliovirus (PV), 
human rhinovirus (HRV) and hepatitis A virus (HAV). 
Picornaviruses share a common replication strategy in which 
the viral  RNA genome is translated  in the cytoplasm of infected 
cells as a long polyprotein precursor that is  cleaved by virally 
encoded proteases to release the functional  proteins  needed for 
synthesis  of new virions. In all  cases, the 3C protease (3Cpro) 
performs the majority of these cleavages  (ten out of thirteen for 
FMDV) by targeting specific sequences within the 
polyprotein2,5,6. 
Structural studies on picornaviral 3C proteases revealed an 
overall fold  that  closely resembles the architecture of trypsin-
like serine proteases7-11. The peptide-binding cleft, which 
contains the active site at its centre, is located  at the interface 
between two β-barrels. Unusually, picornaviral 3C proteases 
possess  a Cys-His-Asp/Glu catalytic triad at the centre of this 
cleft instead of the Ser-His-Asp arrangement of active site 
residues that is commonly found in serine proteases12-14. 
Most work to investigate the cleavage specificity of picornaviral 
3C proteases has relied on extensive sequence analyses of the 
cleavage junctions within the polyprotein3,15 or in vitro  cleavage 
assays using protein or peptide substrates8,16-20. There is a 
surprising degree of variability  in the sequences  of the 
polyprotein junctions that  are cleaved by picornaviral 3C 
proteases but these studies have nevertheless been valuable in 
identifying residues in the substrate that  are important 
determinants of cleavage. Most picornavirus 3C proteases 
cleave the peptide bond between a highly conserved P1-Gln/P1´-
Gly pair15,21 [where P1 and P1  ´ denote the first amino acids on 
the N-terminal and C-terminal sides  of the scissile bond 
respectively; in this notation22 the corresponding sub-sites  on 
the enzyme are labelled S1 and S1´]. FMDV 3Cpro is  an 
interesting exception to  this general pattern  since it exhibits a 
preference either for substrates in which P1-Gln is followed by 
a relatively large, apolar amino acid in the P1  ´ position, or for 
P1Glu/P1´Gly junctions3. HAV 3Cpro can also tolerate larger P1´ 
amino acids  in  substrates with P1-Gln21. Other positions in  the 
peptide also contribute to substrate recognition; in general there 
is  a preference for a hydrophobic residue at  P4 16,18,19 and the 
nature of the P2 and P2  ´ amino acids, which vary between 
different picornavirus families, can also be important8.
Extensive structural analysis of trypsin-like serine proteases 
have revealed a common mode of substrate binding in which 
the polypeptide sequence recognised by the enzyme lies in an 
extended conformation, similar to a β-strand, within the peptide 
binding cleft23. These enzymes typically recognise the 
alternating positions  of the side chains along the sequence that 
are characteristic of an extended backbone conformation and 
this  serves to place the scissile bond in the correct orientation at 
the active site. The primary specificity determinants in trypsin-
like serine proteases are commonly  located  within  the P4-P1 
sequence24-26 but  can extend  well  beyond this  core region for 
enzymes that are highly specific27. Crystallographic analysis of 
enzyme-substrate complexes reveals  that viral 3C-like 
proteases, such as  Tobacco Etch Virus NIa protease (TEVpro)28 
or the Severe Acute Respiratory Syndrome Coronavirus Main 
protease (SARS 3CLpro)29, fall  into the latter group since 
contacts with the enzyme can involve up to five or six amino 
acids on either side of the cleavage site. However, although both 
these proteases are ‘3C-like’  in structure and have the common 
trypsin-like fold, they exhibit substantial differences from one 
another and from genuine picornaviral  3C proteases, especially 
in the loops that define the peptide-binding surface. 
Previous structural analyses of picornavirus 3Cpro-peptide 
complexes have used relatively short, covalently attached 
peptides or peptide-mimicking inhibitors. In most cases the 
inhibitors were designed to bind to the S4-S1 sub-sites24-26, 
though there is one report  of the structure of an inhibitor bound 
to  the S1´-S2  ´ sub-sites30. These studies are a powerful 
complement to  cleavage assays since they have helped to 
elucidate the structural basis of amino acid recognition by  these 
enzymes, particularly  on the N-terminal side of the scissile 
bond. However, these studies cannot give a complete picture of 
protease-substrate interactions since in each  case the peptide is 
covalently attached to the protease and represents  at most one 
half of the peptide substrate that is recognised by the enzyme.
Here we report  the first crystallographic analysis of a 
picornaviral 3Cpro complexed with an intact peptide substrate 
that spans P5-P5´. Our structural analysis  of FMDV 3Cpro is 
combined with peptide cleavage assays  that have examined the 
effect on specificity  of amino acid  variations within P5-P4  ´ and 
of mutations in the peptide-binding cleft of the enzyme. This 
concerted investigation provides a detailed and insightful 
description of the interactions between enzyme and substrate. 
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TABLE 1: Data collection and refinement statistics
DIFFRACTION DATA
Peptide complex VP1-2A VP1-2Am
Synchrotron ESRF ID23-2 ESRF ID14-2
Space-group P212121 P21
a, b, c (Å) 64.8, 75,3, 86.0  64.0, 75.1, 86.3
α, β, γ (°) 90, 90, 90  90, 99.3, 90
Resolution range (Å)1  30.3 - 2.5 
(2.66-2.5)
 63.2- 2.7 
(2.87-2.7)
Independent reflections 14044 16981
Multiplicity2 4.4 (2.5) 2.4 (2.6)
Completeness (%) 93.4 (78.5) 76.1 (60.8)
I/σI 9.1 (2.5) 8.6 (3.2)





Rcryst (%) 21.2 23.6
Rfree (%) 26.7 29.1
r.m.s bond lengths (Å) 0.008 0.008
r.m.s bond angles (°) 1.29 1.33




PBD ID 2wv4 2wv4
1Resolution ranges for the highest resolution shells given in 
parentheses. 2Values for the outermost resolution shell given in 
parentheses.
Most strikingly we find that 
s i g n i f i c a n t c o n f o r m a t i o n a l 
adaptation by the enzyme is 
important for substrate recognition. 
This helps to explain several 
important aspects of specificity 
d i ffe rences be tween the 3C 




In conjunction with our structural 
analysis we performed an extensive 
investigation of the impact of 
sequence variation in the peptide on 
the rate of cleavage by FMDV 
3Cpro . Fo r t hese a s says  we 
synthesised a series of variants of 
FRET4, a modified peptide based 
on  the P5-P8  ´ region of the VP1-2A 
cleavage junction31, one of the ten 
sites cleaved by FMDV 3Cpro in  the 
viral  polyprotein. Cleavage of 
F R E T 4 p r o d u c e s a r e a d i l y 
detectable increase in fluorescence31 
(Materials and Methods). The 
FRET4 variants, which contained 
single amino acid substitutions at 
positions  P5-P1  ´ and P4´, or a 
double-substitution at P1 and P1´, 
were used in cleavage assays  to 
determine the relative value of the 
specificity constant (kcat/KM) in each 
case (Fig. 1a). 
A detailed account  of the results  of 
these experiments will be presented 
alongside the description of the 
structural features of peptide-
protease interactions at each 
posi t ion along the substrate 
sequence (see below). Overall it  is 
notable that—within the context of 
the VP1-2A sequence—variation at 
all positions from P4 to P1´ 
inclusive can reduce the rate of 
peptide cleavage by FMDV 3Cpro to 
between 0 and 50% of the rate 
observed with the control peptide 
(Fig. 1a). In contrast, variation at 
the P5 and P4  ´ positions at the 
extremities of the peptide had little 
impact on peptide cleavage. With 
one exception, these results  are 
consistent with previous alanine-
scanning analysis of the peptide8. 
They confirm the importance of 
positions P4, P2, P1 and P1  ´ for 
substrate recognition but reveal—
for example—that residues at the P3 
position can also contribute to 
cleavage specificity. The only 
incons i s t ency no ted i s t ha t 
substitution  of P4´-Phe (by Arg, Pro 
or Ala) had little effect on peptide 
cleavage in the fluorescence assay 
whereas previously it had been 
found in  a HPLC-based assay that 
substitution by Ala abrogated 
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Figure 1: Overview of  peptide recognition by FMDV 3Cpro. (a) Relative cleavage activity of 
FMDV 3Cpro against variants of the FRET4 substrate with amino acid substitutions in positions P5 
to  P4´. The activity is normalised with respect  to the cleavage rate observed with wild-type 
substrate (Materials and Methods). The amino acids in the wild-type sequence are given at the top 
of each section; the identity of the substituted amino acid is given along the bottom. Note that  in 
the P1/P1  ´ panel the Glu/Leu and Gln/Gly data bars are for single P1 and P1  ´ mutants 
respectively, but are duplicated here for ease of comparison with the Glu/Gly double mutant. (b) 
Schematic view of the co-crystal  structure of 3Cpro (with N- and C-terminal β-barrels coloured 
lilac and green respectively) complexed with the VP1-2A peptide. The peptide is  depicted in sticks 
colour-coded by atom type (carbon – orange; oxygen – red; nitrogen - blue) with its  Van der Waals 
surface shown as a semi-transparent surface. (c) Surface representation of FMDV 3Cpro complexed 
with  the VP1-2A peptide (sticks), coloured as in panel  b. (d) Surface representation of TEV NIa 
3C-like protease complexed with a P7-P3´peptide 28. The N- and C-terminal β-barrels are coloured 
cyan and tan respectively). (e) Superposition of the free (grey) and peptide-bound (purple) forms 
of FDMV 3Cpro. The viewpoint is similar to that  of panel b. Backbone-backbone hydrogen bonds 
are shown as  purple dashed lines;  other hydrogen bonds are coloured orange. Selected side chains 
are shown as sticks;  secondary structural features  that show greatest movement on peptide binding 
are labelled. Note that the unbound structure of FMDV 3Cpro has a Ser at position 142 (ref. 12).
cleavage 8. The origin of this discrepancy is unknown but the 
structural results are consistent with the more recent findings 
that the P4  ´ residue is unlikely to contribute significantly to 
substrate specificity (see below).
Structure determination
Recombinant type A1061 FMDV 3C protease, inactivated by 
mutation of the active site Cys  to Ala (C163A) and containing 
the C95K and C142L substitutions necessary  for enhanced 
solubility12, was purified from E. coli and co-crystallised with a 
five-fold molar excess of the decameric peptide, VP1-2A 
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Figure 2: Structural details of peptide recognition by FMDV 3Cpro. (a) Close-up view of the binding of the P5-P1 residues from the 
VP1-2A peptide. The protease backbone is depicted as a smooth ribbon, covered by a semi-transparent grey Van der Waals surface; 
selected side-chains are shown. (b) Close-up view of the binding of the P1´-P4  ´ residues from the VP1-2A peptide. Detailed views of 
the P1-P1  ´ interactions for (c) FMDV 3Cpro complexed with VP1-2A and (d) FMDV 3Cpro complexed with VP1-2Am. The two 
hydrogen bonds made by OE1 from the P1-Glu side chain to  Thr 158  and His 181 are shown as dotted lines; atom OE2 from the P1-Glu 
side chain is too distant from Thr 158 to form a hydrogen bond. (e) HRV 3Cpro complexed irreversibly with a peptide-like inhibitor25. (f) 
TEV NIA 3C-like protease complexed with a P7-P3´ peptide28.
(Materials and Methods). This peptide spans the P5-P5´ 
positions22 and  contains the sequence APAKQ|LLNFD from the 
VP1-2A junction in  the polyprotein that was  cut most rapidly in 
peptide cleavage assays8. The protease:peptide complex yielded 
crystals in space-group P212121 that  diffracted X-rays to 2.5 Å. 
The structure was determined by molecular replacement 
phasing using the structure of the free enzyme (PDB-ID 2j92; 
ref. 12) as a search model. There are two molecules in the 
asymmetric unit  and the initial  difference electron density map 
revealed clear density for the peptide bound to each molecule. 
The density was of high quality, consistent with full occupancy 
of the binding site, and readily allowed determination of the 
side-chain conformations for nine of the ten amino acids (P5-P4
´) in  the peptide. The electron density at the C-terminal end of 
the peptide was  too weak to permit  incorporation of the P5´-Asp 
residue in the refined  model  (Supplementary  Fig. 1a). Atomic 
structures of the two 3Cpro-peptide complexes in the crystal 
were built using O32 and refined with CNS33 to yield a model 
with an Rfree of 26.7% and excellent stereochemistry (Table 1).
An identical approach was applied to the preparation and 
structure determination of the complex of 3Cpro with  the 
modified VP1-2Am peptide, which contains a Gln-to-Glu 
substitution  at the P1 position. Although this peptide differs  by 
only  one amino acid from VP1-2A, the 3Cpro:VP1-2Am 
complex yielded crystals of a different space-group (P21) that 
diffracted to slightly lower resolution (2.7 Å). The dataset  is 
only  76% complete but averaging across the four molecules in 
the asymmetric unit yielded a good quality electron density map 
(Supplementary Fig. 1b) that provided a clear indication of the 
bound conformation of residues P5-P4  ´ of the VP1-2Am 
peptide. The refined model has an Rfree of 29.1% (Table 1).
Overview of the structure
The overall  structures of the 3Cpro-peptide complexes obtained 
with  VP2-2A and VP12Am are very similar to one another 
(Supplementary Fig. 2). There are differences in the backbone 
conformations of residues 105-109 at the C-terminal end of the 
polypeptide linking the two βbarrels of the enzyme, indicative 
of flexibility in this portion of the backbone. However, this is 
unlikely to impact peptide recognition since this part of the 
linker runs along the underside of the C-terminal β -barrel, 
opposite to the surface containing the peptide binding cleft.
When viewed with the inter-domain cleft aligned vertically (as 
in  Fig. 1b,c), the peptide is observed to bind largely within a 
deep surface-groove that is  oriented diagonally and intersects 
the cleft  at the active site. Consequently residues P5-P1 on the 
amino-terminal side of the scissile bond mainly contact the C-
terminal β-barrel, while residues P1´-P5  ´ interact primarily with 
the N-terminal β-barrel. The length of the recessed groove is 
sufficient to accommodate residues P4-P2  ´ of the peptide 
though residues outside this core are also  in contact with the 
surface of the protease. 
Conformational changes associated with binding
Comparison of the bound and free12 forms for FMDV 3Cpro 
reveals several  conformational changes that can be ascribed to 
peptide binding because they are observed for the six 
independent structures found in the asymmetric units of the 
crystals of both 3Cpro-peptide complexes, all of which have 
different packing environments in the crystal. These differences 
extend across both β-barrels (Fig. 1e; Supp. Movie 1). On the 
P5-P1 side the β-ribbon (residues 138-150) moves in to contact 
the peptide and there are adjustments in the backbone of the 
polypeptide that form the flanks of the S1 sub-site (β-strand E2 
and the C-terminal end of the C2D2 loop) (Fig. 1e); on  the P1´-
P5  ´side of the peptide the most significant changes in backbone 
conformation occur in residues 47-53 and the nearby A1-B1 pair 
of β-strands  (residues 18-31) that are in  closest contact with the 
peptide. These two segments of polypeptide are altered due to a 
propagated series of side-chain movements  initiated by the 
rotation of the side chain of Leu 47 that is necessary to 
accommodate the P1´-Leu residues of the peptide (see below). 
Structural basis of peptide binding specificity
The extensive malleability of the peptide-binding surface allows 
the protease to form intimate contacts with the substrate along 
most of its length. In  common with other trypsin-like proteases, 
there is  a network of hydrogen bonds between the peptide and 
protease backbones that mimics the interactions between 
protein β- strands. In the case of the complex between FMDV 
3Cpro and the VP1-2A peptide, there are nine such main-chain 
hydrogen bonds  in total, extending from P4-Pro to P5´-Asp 
(Fig. 1e). These main-chain contacts are bolstered by hydrogen 
bonds and apolar contacts between the peptide side chains  and 
the protease. We will consider each of these in detail.
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Figure 3: Mutagenic analysis of  S1´ specificity. (a) 
Schematic diagram of the inactive polyprotein precursor used 
as a substrate in these cleavage assays which contains  three 
cleavage junctions44. The P5-P5  ´ sequences of the three 
cleavage junctions in this polyprotein are 3B1/3B2 – LPQQE|
GPYAG; 3B2/3B3 – PVVKE|GPYEG; 3B3/3C – LIVTE|
SGAPP. The sizes of the primary cleavage products  are 
indicated. (b) SDS-PAGE analysis of polyprotein precursor 
digestion by FMDV 3Cpro S1  ´ mutants  at 10 and 60 minutes. 
Labels on the right hand side indicate the substrate (Sub.), the 
active 3Cpro (3Cact) and the primary cleavage products (Prod.). 
(c) Comparative activity  of FMDV 3Cpro S1  ´ mutants measured 
in  the fluorescent peptide cleavage assay using the synthetic 
FRET4 substrate31, which contains the VP1-2A cleavage 
junction (Materials and Methods). Data shown are the average 
fluorescence units from 3 experiments ±SEM.
P5-Ala at the N-terminus of the peptide is largely solvent-
exposed (Fig. 2a). The side chain points towards the 
hydrophobic side chain of Met 143 but is  too far away (4.7 Å) 
to  make contact. This lack of contact accounts for the finding 
that substitution by Arg, Leu or Pro at this position has only a 
modest effect on substrate cleavage, reducing the rate by two-
fold at most (Fig. 1a). 
P4-Pro, by contrast, is accommodated in a shallow, apolar 
depression that  marks the beginning of the peptide-binding 
groove and is formed by the side chains  of Leu 142 (Cys in the 
wild-type protein12), Val 140 and Tyr 190 (Fig. 2a). The P4-Pro 
side chain  is  not completely buried since one flank, containing 
the Cδ atom faces outward and is solvent-exposed. This part of 
the side chain is quite close to the carbonyl oxygen of Val 141 
and side-chain hydroxyl of Tyr 190 (4.2 Å in each case). 
Intriguingly, mutation of the P4 residue to Val, Leu or Ile 
completely abrogated cleavage of the fluorescent substrate (Fig. 
1a), consistent with a previous observation that an Ala 
substitution  at this  position also prevented cleavage8. These 
results suggest that, at least within the context of the VP1-2A 
peptide, there is a strict requirement for P4-Pro. Although the 
structure suggests  that Ala and Val side chains, which are 
similar in size to Pro, should be accommodated in the S4 
pocket, they  may nevertheless affect the binding conformation 
sufficiently to  prevent proper presentation of the scissile bond to 
the active site. This is a rather surprising result given the 
evident malleability of the protease. It is also unexpected since 
Ala, Val and Ile are observed at  P4 in  other FMDV polyprotein 
cleavage junctions, albeit  within the context of different 
sequences [see Table II in 8].  
The side chain of P3-Ala points towards solvent but packs 
against Met 143 at the apical tip of the β-ribbon that alters its 
conformation on peptide binding to  contact the P  side of the 
substrate (Fig. 2a; Supp. Movie 1). This explains why, in 
common with other similar proteases, there is  no strong 
preference for particular residues at this position in natural 
cleavage junctions3. In  sequences cleaved by FMDV 3Cpro Val, 
Gln, Glu, His, Phe, Ser, Arg and Ala are found at  P3, all of 
which could make some hydrophobic contact  with the side 
chain of Met 143. Nevertheless, variation of this residue to Gln, 
Glu or Val within the context of the VP1-2A peptide reduces 
cleavage rates 5-10 fold, demonstrating that variation at the P3 
position  can affect cleavage (Fig. 1a). It may be that  these larger 
side chains affect the positioning of the β-ribbon, which then 
has a knock-on effect on peptide interactions at other sub-sites. 
The P2-Lys side chain inserts into the cleft between the β-
ribbon and the body of the N-terminal β-barrel  of the protease 
(Fig. 2a). On one side the Lys side chain primarily  contacts the 
side chain  of His 46 (the central residue of the catalytic triad), 
whereas on the other the aliphatic portion  of the Lys  contacts 
the apolar side chains  of Leu 142 and Met 148. At the distal end 
of the pocket—which is open to solvent—there are salt bridges 
from the amine group at the tip of the Lys side chain to two 
acidic residues from the β-ribbon, Asp 144 (3.6 Å) and Asp 146 
(2.8 Å) (Fig. 2a). Formation of the S2 pocket appears to be 
dependent on peptide binding since Leu 142, Asp144 and 
Asp 146 all  adjust  their positions in the presence of substrate 
(Fig. 1e). The salt bridges  to the pair of Asp residues in the β-
ribbon explains the strong preference for P2-Lys in natural 
substrates, (though it is not yet clear why this preference is 
strongest in  substrates  with P1-Gln3). Consistent with the acidic 
nature of the distal end of the S2 pocket, incorporation at P2 of 
norleucine (which is  structurally  similar to  Lys  but lacks  the 
amine group) abrogates cleavage, whereas substitution by Arg 
or ornithine (both of which have a positive charge at  the tip of 
the side chain) only modestly reduces the rate of peptide 
cleavage (Fig. 1a). Curiously, substitution by Thr also abrogates 
cleavage, even though this  residue is found in other natural 
FMDV 3Cpro substrates8; it may be that Thr is tolerated at  P2 
only  in the context of variation of the amino acids at other 
positions in the peptide substrate.
The side chain of P1–Gln is  accommodated by small  (0.7 Å) 
movements of the two backbone segments that form the flanks 
of the S1 pocket  (residues 158-161 and 183-186) (Fig. 1e). The 
P1 side chain makes three hydrogen bonds to  the pocket, two 
between the carbonyl  group and the side chains of His 181 and 
Thr 158 (2.6-2.9 Å) and one from the amide group to the 
backbone carbonyl of Thr 158  (3.2-3.5 Å) (Fig. 2a,c). The 
pocket therefore displays good chemical complementarity to the 
P1-Gln  side chain. However, peptide cleavage assays previously 
showed that incorporation of Glu at this position  only reduces 
the cleavage rate by a factor of two8, consistent with the 
common occurrence of P1-Glu in FMDV 3Cpro substrates3. To 
investigate this finding in more detail, we determined the crystal 
structure of 3Cpro bound to a modified VP1-2A peptide, in 
which P1-Gln is substituted by P1-Glu (VP1-2Am). The 
structure reveals that  the P1-Glu side chain binds in a manner 
that is almost identical to that  observed for P1-Gln in  the 
VP1-2A peptide (Fig. 2c,d). One oxygen atom from the P1-Glu 
side-chain carboxylate (OE1) makes two hydrogen bonds 
(ranging in length from 2.4-2.8 Å over the four independent 
structures) to His 181 and Thr 158; but the other carboxylate 
oxygen (OE2) is more distant from the main-chain carbonyl 
oxygen of Thr 158 (3.2-3.7 Å) and — assuming that  the side-
chain carboxylate is deprotonated — cannot form a hydrogen 
bond. The fact that the OE2 oxygen is also exposed to solvent 
(Fig. 2d) may also attenuate any negative impact on binding by 
allowing access to positive counter-ions in the cytoplasm of 
infected cells.
It therefore appears that the primary interactions to the P1 side 
chain of the substrate are the two shorter hydrogen bonds made 
with  the side chains of His 181 and Thr 158. The longer 
separation between the carbonyl oxygen of Thr 158 and the P1-
Gln amide or the P1-Glu  carboxylate oxygen (OE2) is  likely to 
reduce the impact of these groups on peptide binding, thus 
allowing FMDV 3Cpro to cleave substrates containing either 
type of residue in the P1 position. The importance of the 
hydrogen bonds  to the side chains of His 181 and Thr 158 is 
underscored by  the finding that incorporation of uncharged 
(norleucine; Nle),  longer (adipic acid; Adi) or shorter (Asp) 
carboxylated side chains at P1 prevents cleavage of the 
substrate by FMDV 3Cpro (Fig. 1e). 
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Figure 4: Mutagenic analysis of  D84 from the catalytic 
triad. SDS-PAGE analysis of polyprotein precursor digestion 
by  wild-type FMDV 3Cpro, and the D84A and D84E mutants 
at 5 and 180 minutes. The substrate is the same as depicted in 
Fig. 3a.
The binding of the P1´-Leu side chain is unusual  because it is 
accommodated in a pocket  that  forms only  when the protease 
interacts with the peptide substrate (Fig. 2b). In the free enzyme 
Leu 47 packs against  Cys 31 to form the floor of a shallow S1´ 
pocket but peptide binding was found to induce rotation of the 
side chain of Leu 47 towards the core of the N-terminal β-
barrel, thereby creating a much deeper compartment to 
accommodate the peptide side chain (Fig. 1e). The largely 
apolar sides of the S1  ´pocket  are formed on one side by Pro 44, 
His 46, Leu 47 and the aliphatic flank of Glu 50 and by Ala 29 
and Cys 31 on the other. The displacement of Leu 47 has 
significant knock-on effects, leading to displacement  of Phe 48, 
Tyr 52, Leu 21, and Ile 55; there is also alteration of the main 
chain conformation of residues 4852 (Fig. 1e; Supp. Movie 1). 
As noted previously3, large hydrophobic side chains at the P1´ 
position  are preferred in natural FMDV 3Cpro substrates 
containing P1-Gln. This correlation of P1 and P1  ´ amino acids 
seems to be necessary for efficient cleavage since substitution 
of P1´-Leu by Gly yielded a ten-fold reduction in cleavage rate, 
whereas introduction of Val or Cys at P1  ´ reduced the rate of 
cleavage only two-fold (Fig. 1a). Examination of the structure 
suggests that a P1´-Gly side chain would be too  small even to 
make stabilising contacts with the shallow form of the S1´ 
pocket. 
Since the bound conformations of VP1-2A (P1-Gln) and 
VP1-2Am (P1-Glu) peptides  are very similar, it  was no surprise 
to  find that incorporation of P1´-Gly within the context of the 
VP1-2Am sequence also gave a ten-fold reduction  in the rate of 
cleavage (Fig. 1a). However, these results cannot explain the 
observation that natural FMDV substrates with P1-Glu are most 
frequently observed to have Gly at P1  ´ 3. We suggest that 
sequences beyond the residues on either side of the scissile 
bond  are important in ensuring that it  is  presented optimally to 
the active site.
P2´-Leu binds at one end of the recessed peptide-binding 
groove (Fig. 1b, 2b). The side chain packs against Ala 160, 
Gly 161, Ile 30 and the Cβ group of Asp 123 and against the 
side chain of P4´-Phe from the peptide, but is  still  only partially 
shielded from solvent (Fig. 2b). The interaction between the P2´ 
and P4  ´ side chains may not be replicated in  other peptides 
since neither position is particularly  well conserved in 
polyprotein junctions cleaved by 3C (ref. 34). The apolar nature 
of the S2  ´binding pocket  explains the general preference for P2
 ´ residues with  some hydrophobic functionality (Ser, Lys, Thr, 
Leu in P1-Gln substrates; Pro, Gly, Leu and Ile in P1-Glu 
substrates).
The P3´Asn side chain is almost completely solvent-exposed 
but is positioned to form a hydrogen bond with Glu 50 on the 
enzyme surface (Fig. 2b). However, there is  little sequence 
conservation at this position in FMDV 3Cpro substrates  and the 
most common alternative P3  ´ residues (Tyr, Ala, Ile) would not 
maintain this interaction. The exposed position of P3´Asn 
explains why an EDANS group can be added to an Asp side 
chain at this position in the FRET4 peptide substrate without 
compromising its ability to be cleaved by FMDV 3Cpro 31.
P4´-Phe is also largely solvent-exposed and primarily contacts a 
small apolar patch on the upper surface of the C-terminal β-
barrel formed by the side chain of Ile 30 and the methyl  group 
of Thr 27 (Fig. 2b). The hydrophobic nature of this patch 
explains the general preference for residues with apolar side 
chains at P4  ´ 3. Consistent  with this  notion substitution of P4´-
Phe by Arg, Pro or Ala, all of which have significant apolar 
features, only modestly reduced the rate of peptide cleavage 
(Fig. 1e). 
The position of P5´-Asp is  unknown since there is no electron 
density for this residue. It appears to make no stabilising 
contacts with the protein, in agreement with the observation that 
mutation to Ala at P5  ´ had no effect of the rate of peptide 
cleavage8. 
Mutagenic analysis of the S1´ specificity pocket
As described above, the co-crystal structure of 3Cpro with the 
VP1-2A peptide revealed that binding of the peptide 
necessitated movement of Leu 47 to create a pocket deep 
enough to accommodate the P1´-Leu side chain (Fig. 1e). This 
S1  ´ pocket is the site of an interesting difference in specificity 
between FMDV 3Cpro on the one hand and 3Cpro from HRV and 
PV on the other. Whereas FMDV 3Cpro preferentially cleaves 
Gln-Xaa junctions, where Xaa is predominantly Leu, Ile or 
Thr3, HRV and PV 3C proteases have a marked preference for 
cleavage at Gln-Gly junctions15. Comparison of the protease 
structures readily accounts for this difference since the Cys 31/
Leu 47 residues that form the floor of the shallow S1  ´ pocket in 
the free form of FMDV 3Cpro are replaced by Phe 25/Ala 41 in 
3Cpro from HRV [PDB-ID 1cqq;  ref. 25] and PV [PDB-ID 1l1n; 
ref. 10] (Fig. 2c,e; Supp. Fig. 4). Examination of these 
structures suggests that steric hindrance would prevent the 
movement of Phe 25 that would be necessary  to accommodate a 
large P1´ side chain.
We explored this idea by mutating the S1  ´ pocket on FMDV 
3Cpro to make it resemble HRV 3Cpro and testing  the effect on 
cleavage activity on a 3BC polyprotein substrate that contains 
Glu-Ser and Glu-Gly cleavage junctions, i.e. it  has  a small P1´ 
side chain (Fig. 3a; Materials and Methods). In this assay, the 
primary cleavage observed is  at the Glu-Ser junction; further 
cleavage at the Glu-Gly junctions within 3B1-3B2-3B3 may be 
impeded by the low solubility of this fragment (Fig. 3a,b). 
Under the assay conditions used, wild-type FMDV 3Cpro 
cleaves over 95% of the substrate within 10 minutes. The single 
mutation C31F drastically reduced the ability of the protease to 
cleave this protein substrate;  no cleavage was evident after a 1-
hour incubation (Fig. 3b) and very partial cleavage was 
observed after 4 hours (Supp. Fig. 3). We estimate that the 
reduction in activity is approximately 200-fold. In contrast, 
mutation to the much smaller Ala side chain (C31A) had 
essentially no effect on the proteolytic activity of 3Cpro in this 
assay (Fig. 3b). The considerable reduction in the protease 
activity due to the C31F substitution is probably due to the 
steric strain that arises from close-packing of the large side 
chains of Phe 31 and Leu 47 in the S1  ´ binding pocket  of the 
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Figure 5: Infectivity of  C142L mutants of  O1K FMDV. 
Single step growth curves of wild-type O1K FMDV and two 
mutant viruses, both containing the C142L mutation in the 
βribbon of 3Cpro. The virus yield was determined by measuring 
the number of FMDV RNA genomes in a real-time RT-PCR 
assay (Materials and Methods).
mutant, which may have a knock-on effect on the position  of 
His 46, a key component  of the catalytic triad (compare Fig.s 2c 
and 2e;  Supp. Fig. 4). This  interpretation is strongly supported 
by  the finding that the C31F/L47A double-mutation, which 
reduces the size of the side chain opposite Phe 31 and generates 
an S1  ´ pocket that resembles that found in HRV and PV 3Cpro, 
restores near wild-type cleavage activity (Fig. 3b). The C31A/
L47A double-mutant is slightly  impaired compared to the wild-
type protease, perhaps because the P1  ´ residue is bound less 
tightly in the enlarged S1´ pocket. 
We also investigated the impact of these S1  ´ mutations on 
cleavage of the fluorescent FRET4 substrate, which is based on 
the sequence of the VP1-2A peptide and contains a Gln-Leu 
cleavage junction; this substrate therefore places a large, 
hydrophobic side chain (P1´-Leu) in the S1  ´ pocket. As found 
previously, the C31F mutant showed the greatest impairment of 
cleavage activity, although the 7-fold reduction  in cleavage rate 
compared to wild-type was much less than the ~200-fold 
reduction observed in the polyprotein cleavage assay (Fig. 3b). 
The precise reason for the difference in the magnitude of effect 
is  not clear, but may relate to the different sequences that are 
being cleaved in the two experiments.
Strikingly, and in contrast to the result  obtained with a substrate 
containing a small P1  ´ amino acid (Fig. 3b), the double 
mutation C31F/L47A did not rescue wild-type activity with the 
FRET4 substrate (though, as expected, the enzyme was slightly 
more active than the C31F single mutant) (Fig. 3c). Overall, 
these results are consistent with the structural data: the C31F/
L47A double mutation  would  be predicted  to make the S1´ 
pocket on FMDV 3Cpro resemble the inflexible, shallow 
depression found in  the HRV enzyme (Supp. Fig. 4) which has a 
preference for substrates with a small P1´ residue.
Curiously the single C31A mutation reduced the rate of 
cleavage of the fluorescent  VP1-2A peptide by about three-fold 
(Fig. 3c). This loss of activity possibly occurs because the P1´-
Leu of the substrate was bound less snugly  by the enzyme. As 
before the C31A/L47A double mutation caused only a very 
slight further reduction of the cleavage activity. 
Mutagenic analysis of the catalytic Asp
The crystal structure of the 3Cpro-peptide complex reveals that 
the conformation of the catalytic triad is unchanged by peptide 
binding (Fig. 1e). In particular, it shows that  Asp 84, the acidic 
member of the catalytic triad, maintains a hydrogen bond 
interaction with His 46, supporting the idea that this unusual 
class of trypsin-like cysteine proteases requires a full Cys-His-
Asp triad  for catalytic activity8,14. We tested this hypothesis  by 
mutating Asp 84 (Fig. 4). The mutation D84E, which maintains 
a carboxylate side chain, reduced cleavage activity by  about two 
orders of magnitude under our experimental conditions: 
whereas wild-type 3Cpro cleaved ~50% of the polyprotein  in 5 
minutes at 37°C, the D84E mutant cleaved <10% of the 
substrate after 180 minutes (Fig. 4). The mutation D84A was 
even more deleterious: there was no discernable cleavage of the 
substrate after 3  hours, consistent with a reduction in activity  of 
at least three orders of magnitude. 
These findings  were confirmed in more quantitative assays 
using the fluorescent FRET4 peptide substrate (Supp. Fig. 5). 
Cleavage by the D84E mutant was about  200 times slower than 
by  wild-type FMDV 3Cpro. Cleavage by the D84A mutant was 
at least  1000 times slower and was beneath the detection level 
of the assay.  
Our results indicate that  mutation of Asp 84  is even more 
deleterious to 3Cpro activity than was  reported previously35. This 
apparent discrepancy is likely due to the greater sensitivity  of 
our assay, which examined cleavage over a range of time points 
(Fig. 4). Our findings confirm the importance of Asp 84 for 
cleavage activity by FMDV 3Cpro and explain the strict 
conservation of this residue in all serotypes of FMDV4. 
Role of the β-ribbon in catalysis
The contacts that the side chain of Leu 142 in the β-ribbon 
makes with  apolar features on  P4-Pro  and P2-Lys in the co-
crystal structure explain the importance of this residue to 
catalytic activity (Fig. 1e, 2a)12. In FMDV 3Cpro this  residue is 
strictly conserved as Cys4, which is also apolar. Previously we 
mutated C142 to  prevent aggregation of the protein due to 
formation of intermolecular disulphide bonds but found that 
substitution  by a large hydrophobic side chain was necessary to 
preserve the catalytic activity of the protease12,13. Although 
slightly  larger, Leu is a reasonable structural mimic of Cys, and 
the structure of the 3Cpro-peptide complex confirms our 
previous conclusion that the apolarity  of C142 in the wild-type 
protein is necessary for its  interaction with the P4 and P2 
residues to ensure correct  presentation  of the polypeptide 
substrate to  the active site12. Consistent  with  this idea, 
introduction of the C142L mutation into a type O1K FMDV had 
no  significant effect  on the infectivity of the virus in tissue 
culture (Fig. 5). This observation and the fact that  the equivalent 
residue in  HRV and PV 3Cpro is  a leucine (Leu 127) 
nevertheless beg the question: why is Cys 142 strictly 
conserved in  FMDV 3Cpro?  We speculate that  this may confer a 
selective advantage during infection of natural hosts by 
permitting inactivation of the protease upon cell lysis. 
Discussion
An extensive, flexible interface for peptide recognition
We have determined the crystal structure of FMDV 3Cpro in 
complex with a specific peptide substrate, providing the first 
detailed view of enzyme-substrate interactions for this 
important group of picornavirus proteases. The mode of peptide 
binding is similar to that observed in HRV and HAV 3C 
proteases complexed with  covalently  attached peptide-like 
inhibitors24-26 and with peptide complexes of other trypsin-like 
proteases36 in that the peptide adopts a linear extended 
conformation that places the P1  side chain  into the S1 
specificity pocket  within the C-terminal  β-barrel, immediately 
adjacent to the catalytic triad. The mode of binding in FMDV 
3Cpro involves  the five mainchain-mainchain hydrogen bonds 
involving the P3-P1  ´ positions on the peptide that are conserved 
in  trypsin-like proteases and appear to be necessary for proper 
positioning of the scissile bond in the active site27.
However, the structure reveals that  the enzyme-substrate 
interaction extends well outside this core region; all  side chains 
from P4P4  ´ are involved to  a greater or lesser extent in  contacts 
with  the surface of 3Cpro. Overall the structure of the complex is 
highly  consistent with the results of experiments to probe the 
effect of variation of the side chain at different positions within 
the peptide substrate on cleavage rates, which suggest  that the 
region P4-P2  ´ contributes  most to peptide specificity. This  is 
probably because these six residues occupy the deepest part of 
the surface groove that forms the peptide-binding cleft (Fig. 1c).
There are nevertheless some unexpected results  from the 
cleavage assays that  are not readily explained by the structure. 
For example, it is notable that, within the context of the VP1-2A 
cleavage junction sequence, conservative substitution of P4-Pro 
with  residues such as Val or Ala that  occur at this  position in 
other junctions, leads to complete abrogation of peptide 
cleavage (Fig. 1a). The effect of these substitutions is all the 
more surprising given  the evident  flexibility displayed by the 
protease (Fig. 1e; Supp. Movie 1) but it is perhaps a reflection 
of the important role played by sites  remote from the scissile 
bond in peptide cleavage efficiency27,36.
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The extensive interface of contact between the peptide and 
protease in FMDV 3Cpro exhibits similarities to that observed in 
the 3C-like TEVpro, which was solved in complex with  a peptide 
that spanned positions  P7-P3  ´ 28 (Fig. 1c,d). Superposition of 
the two structures shows that  the backbone geometry is  similar 
over the common P4P3  ´ region. The structural  similarity is 
closest for the core segment centred on  the scissile bond (P2-P2
´; root-mean-squared deviation over Ca = 0.14 Å), but there are 
significant structural  deviations  outside this region, dictated  by 
the differing topologies of the peptide-binding cleft. In 
particular, TEVpro provides  a much more enclosed binding site 
for the P4-P3 residues due to the close apposition of the C-
terminal β-ribbon with the E2F2 loop  in the C-terminal β-barrel 
(Fig. 1d). 
The FMDV 3Cpro-peptide interaction is also reminiscent of the 
extended interface observed in structures  of specific protein 
inhibitors  of trypsin  and trypsin-like proteases such as 
chymotrypsin and collagenase37-41. These inhibitors are 
generally composed of a small stable domain that interacts with 
the target  enzyme by inserting an extended internal  loop, 
constrained at both ends, to the peptide-binding cleft of the 
target enzyme. The extent of the interaction varies  from P3-P2´ 
in  the complex of trypsin with pancreatic trypsin inhibitor40 to 
P7-P4  ´ for ecotin bound to collagenase38. These inhibitors 
strongly mimic highly specific substrates but are usually 
cleaved extremely slowly because the rigidity of the enzyme-
peptide interface prevents  the conformational changes necessary 
to  attain the tetrahedral  intermediate at the scissile bond and the 
tightly packed interface prevents access of water molecules that 
would be necessary for the deacylation step of catalysis42. In 
contrast, in 3C proteases extensive sequence recognition  must 
also be allied with sufficient flexibility to permit catalysis. 
Although the residual flexibility in the 3Cpro-peptide complex 
that is necessary for catalysis is not detectable by 
crystallography, our results  do reveal  that  structural adjustments 
are made across  the peptide-binding surface upon substrate 
binding. Particularly notable are the movements of the β-ribbon 
to  form the S2-S4 sub-sites, the strands flanking the S1 pocket 
and the large rotation of Leu 47 within the S1  ´ pocket  to 
accommodate the large P1  ´ side chain (Fig. 1e). These 
observations are broadly consistent  with previous NMR 
analyses of HRV 3Cpro which revealed flexibility throughout the 
enzyme that was  attenuated by interactions between the protein 
and a peptide like inhibitor spanning P6-P124. These marked 
conformational changes associated with  peptide binding to 
FMDV 3Cpro are in contrast to the relatively  rigid lock-and-key 
binding of some protein inhibitors to trypsin-like proteases37,41 
and underscore the importance of structural analysis of the 
peptide-bound form for obtaining a more complete picture of 
the substrate basis of cleavage specificity. This  information is of 
particular relevance to inhibitor design though further structural 
analyses of FMDV 3Cpro bound to different peptide sequences 
will  be needed to map out the full  extent of structural changes 
that accompany substrate binding.
The conformational changes propagated by rotation of Leu 47 
to  accommodate the P1  ´ Leu in the FMDV 3Cpro substrate were 
unanticipated. Our structural  and mutagenic analyses suggest 
that such side chain movements are very unlikely to occur in 
HRV or PV 3Cpro since the F25/A41 pair of residues that lie on 
either side of the pocket entrance (equivalent to C31/L47 in 
FMDV 3Cpro) do not have the flexibility to accommodate large 
P1  ´ side chains (Fig. 2c-e). This  explains  the strict requirement 
for small P1  ´ side chains — most often Gly — in substrates for 
3Cpro from HRV and PV15,21. In contrast, HAV 3Cpro, like 
FMDV 3Cpro, is  tolerant of larger P1  ´ residues (e.g. R, V, M)21. 
Since it has an M29/A45 pair of residues flanking the S1´ 
pocket, we suggest that the Met 29 side chain may have the 
ability to move to accommodate larger P1´ side chains. 
S1 specificity
The crystal structures of FMDV 3Cpro in complex with the 
VP1-2A and VP1-2Am peptides show that  P1-Gln or P1-Glu 
bind  similarly within the S1 specificity pocket, both making 
hydrogen bonds  from a side-chain oxygen atom to the side 
chains of Thr 158 and His 181; Tyr 154 also plays an important 
role in determining P1 specificity  since it stabilises the 
orientation of His 181 (Fig. 2c,d). This structural arrangement 
accounts well for the observation that  a Gln to Glu substitution 
at P1 within the VP1-2A peptide only modestly reduces peptide 
cleavage (Fig. 1a,e). 
However, the bound conformation of P1-Gln in FMDV 3Cpro is 
also very  similar to the conformation of the modified glutamine 
observed in the S1 pocket when the peptide-like inhibitor 
AG7088 is bound to HRV 3Cpro 25. Although the glutamine side 
chain was altered to incorporate a lactam ring, glutamine-
specific hydrogen bonds were observed in S1. It is therefore 
difficult to understand why FMDV 3Cpro readily  cleaves 
substrates with P1-Gln or P1-Glu, while HRV 3Cpro exhibits a 
strong preference for P1-Gln substrates15,17,20. The discrepancy 
is  all the more remarkable since the residues primarily 
responsible for P1-Gln or Glu recognition in FMDV 3Cpro 
(Thr 158, Tyr 154, His 181) are conserved in the P1-Gln-
specific HRV 3Cpro and in the P1-Glu-specific V8 protease from 
Staphylococcus aureus43. 
Given the close structural similarity between FMDV and HRV 
3Cpro in the S1 pocket, why does HRV 3Cpro discriminate so 
strongly against P1-Glu?  In the 3CLpro from TEV the selectivity 
for P1-Gln is  enforced by an  interaction between the Gln side 
chain amide and the carboxylate of Asp 148 (Fig. 2f)28; clearly 
the presence of this negatively charged side chain strongly 
disfavours binding of substrates with  P1-Glu. But HRV 3Cpro 
lacks an equivalent  repulsive group (Fig. 2e) and it remains 
unclear how discrimination against P1-Glu substrates is 
achieved. 
It may be worth considering the impact of remote sites on P1 
selectivity in these enzymes. As noted previously3, FMDV 3Cpro 
substrates with P1-Glu most commonly have a small residue at 
P1  ´ and are less  likely to  conserve Lys at P2. Perhaps the 
correlated amino acid variations at these and other positions 
have a positive impact on cleavage of P1-Glu substrates. 
Further exploration of this notion will  benefit from structural 
analysis of a complex of FMDV 3Cpro with a natural P1-Glu 
substrate. 
Materials and Methods
Expression and purification of  FMDV 3Cpro: The original 
construct which expresses a C-terminally truncated, 
catalytically inactive form of the type A10 FMDV 3C protease 
that contains C95K, C142S and C163A substitutions (see Table 
2 in  13), was modified for co-crystallisation trials using 
Quikchange (Stratagene) to engineer an S142L mutation. This 
generates a form of 3Cpro that has wild-type binding activity  but 
remains soluble at purified protein concentrations  in excess of 
10  mg/ml 12. This modified construct was used to generate 
additional 3Cpro variants by the same technique to add 
mutations to the active site and S1  ´ sub-site. FMDV 3C proteins 
were produced in E. coli  and purified essentially as  reported 
previously12,13, although the gel filtration step was omitted. The 
purified proteins were concentrated to 5-6 mg/mL in 50 mM 
HEPES, pH7.1, 400mM NaCl, 1mM βmercaptoethanol and 
stored in small  aliquots  at -80°C before use in protease cleavage 
assays.
A modified pET-FMDV3CXS construct13,44, inactivated by 
introduction of the C163A mutation in 3C, was used to express 
the 35  kD fragment of the FMDV A10 polyprotein that 
corresponds to 3B1-3B2-3B3-3BC. The protein, which has a 
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non-cleavable C-terminal  His-tag was produced in BL21 (DE3) 
E. coli and purified to about  95% homogeneity on TALON 
beads (BD Biosciences) using the same protocol  as for the 
active 3Cpro mutants. 
Peptide synthesis: The peptides for co-crystallisation (VP1/2A 
– APAKQLLNFD; VP1/2Am – APAKELLNFD), synthesised 
by  standard Fmoc solid phase synthesis as  described previously8 
with  acetylation of the N-terminus  and amidation  of the C-
terminus to block  charges, were purified by reversed phase 
HPLC and sequences confirmed by mass spectroscopy. The 
FRET4 substrate (and sequence variants) used in peptide 
cleavage assays was prepared as reported12,31. 
Complex formation and crystallisation: 3Cpro-peptide 
complexes were prepared at a 1:5.5 molar ratio of enzyme to 
peptide since this has  worked well for related proteases28. 
Typically 50 µL of 3Cpro at 17 mg/ml protein in 100 mM 
HEPES, pH 7, 400  mM NaCl, 1 mM EDTA, 2 mM β-
mercaptoethanol, 0.01% (w/v) sodium azide was mixed with 
7 µL of 30 mM peptide dissolved in the same buffer, which 
yielded a final protein concentration = 14.9 mg/mL. The 
complex was incubated with rotation at  room temperature for 1 
hour and used immediately in sitting drop vapour diffusion 
crystallisation trials. Optimised crystals of 3Cpro bound to 
APAKQLLNFD were obtained by mixing 1 µL of complex with 
3 µL taken from a 1 mL reservoir composed of 40-42.5% PEG 
400, 0.2 M LiSO4, 0.1 M Tris, pH 8.0. Similar conditions were 
used to crystallise the complex with APAKELLNFD peptide: 
41-43% PEG 400, 0.2 M LiSO4, 0.1 M Tris, pH 8.0. 
Crystals were soaked for a few seconds in mother liquor that 
incorporated 20% (v/v) glycerol and flash-cooled on beamlines 
ID23-2 and ID14-2 at the ESRF in a stream of N2 at 100 K. 
Diffraction data were processed with MOSFLM and scaled 
using SCALA from the CCP4 suite of programs45. The data for 
the 3Cpro:VP1-2A complex crystals  were phased with PHASER 
(version 1.3.2)46 using the unliganded structure of 3Cpro (PDB 
2j92; ref. 12) as a search model after removal of the most 
mobile surface loops  (residues 74-80 and 138-150). This 
procedure located two molecules in the asymmetric unit with an 
overall log  likelihood gain of 1319. The protease structure from 
this  model was then used to solve the structure of the 
3Cpro:VP1-2Am complex, again using PHASER46. In  that case, 
four molecules were identified in  the asymmetric unit; the 
overall log likelihood gain was 3981. Manual  model  adjustment 
and refinement of both models were performed with O32 and 
CNS47 respectively. 
Polyprotein cleavage assays: The cleavage activity of 
TALON-purified 3Cpro mutants  was assessed using a 
protolytically inactive form of FMDV strain A1061 3BC 
precursor as a substrate13,44. Working stocks of 3Cpro and the 
3BC substrate (Fig. 3a) were prepared at 2 mg/ml  in 50 mM 
HEPES, pH 7.1, 400 mM NaCl and 20 mM DTT. In each  assay 
equal volumes of substrate and 3Cpro were mixed to give a final 
concentration of each of 1mg/ml and incubated at  37°C for 
varying times up to 17  hours. Digestion reactions  were stopped 
by  direct addition of 5 µL of 2  × SDS-sample buffer to 5 µL of 
the reaction  mixture, immediately followed by heating at 95°C 
for 2 min. 
Fluorescent peptide cleavage assays: Assays were performed 
in  96 well plates essentially as described previously12 with 
minor modifications. 50-100 µL of varying concentrations of 
the FRET4 fluorogenic substrate31 was added to an  equal 
volume of enzyme. Final enzyme concentrations were typically 
1-2 µM (Wild-type), 5 µM (C31A, C31F, C31A/L47A and 
C31F/L47A mutants) or 10 µM (D84A and D84E mutants). 
Reactions were performed in triplicate at 37°C in 100 mM 
NaH2PO4/Na2HPO4, pH 7.4, 1 mM ethylenediaminetetraacetic 
acid, 1 mM Tris(2-Carboxyethyl)-Phosphine HCl and 5% 
glycerol. Relative hydrolysis rates  were determined by 
monitoring fluorescence at 2 min intervals for 20-60 min in a 
Cytofluor microplate reader or a Molecular Devices 
SpectraMax M2e. The excitation wavelength used was 335 nm 
and emission was measured at 460 nm. Initial  hydrolysis rates 
were recorded (typically from 0-20 minutes) for each substrate 
concentration and specificity constants calculated by  fitting to 
the Michaelis-Menten equation. 
Infectivity assays: The generation of the C142L sequence 
change within the whole virus (type O1K) was achieved by 
overlap PCR using the pT7S3 infectious copy cDNA plasmid48 
as a template using  the flanking primers  3AEcofor 
(AGGCAGCAATTGAATTCTTTGA) and  3CPstrev 
(CGTTGCCTCCTGCAGAGTGA) plus the degenerate 
m u t a g e n i c o l i g o n u c l e o t i d e s 3 C m u t C 1 4 2 L f o r 
(ACTTACAAGGACATTGTGGTTCTNATGGACGGAGACA
C C A T G ) a n d 3 C m u t C 1 4 2 L r e v 
(CCGTCCATNAGAACCACAATGTCCTTGTAAGT). Up to 4 
different codons (CTN) for leucine (L) could have been 
generated to replace the cys (C) residue codon (TGC) in this 
procedure but  just 2 were used.  The mutant PCR product 
including the EcoRI (nt  5058) - Pst1 (nt 6209) region 
(numbered according to Accession no. X00871) was inserted 
into pCR-XL-TOPO vector (Invitrogen) and individual 
plasmids were sequenced. The EcoRI-PstI fragments containing 
the CTA codon (C142L1) and CTG codons (C142L2) were 
excised and reconstructed into  pT7S3 via an intermediate 
plasmid containing the BamHI fragment (nt  2909- nt 7117). The 
full-length wt and  mutant plasmids  were linearized with HpaI 
and RNA transcripts were prepared using T7 RNA polymerase 
(T7 Megascript  kit, Ambion). The transcripts were introduced 
into  BHK cells  by electroporation, essentially as described 
previously49. Complete cytopathic effect was apparent 
following overnight incubation. The rescued virus harvests were 
passaged once in BHK cells and then RNA was extracted using 
a viral RNA extraction kit (Qiagen). RT-PCR reactions, (+/-) the 
reverse transcriptase, were performed using the primers 
(3AEcofor and 3CPstrev, as above) for 25 cycles. The expected 
products were only observed in the presence of the RT, (this 
ensured that products were derived from the viral RNA and not 
from residual cDNA template), the amplicons were then 
sequenced, using the same primers, and had maintained the 
respective wt or mutant sequences  as anticipated (data not 
shown).
A single step growth curve of the rescued viruses was 
performed within BHK cells which were infected with wt or 
mutant viruses, in parallel, and the cells were harvested at t = 0, 
2, 4 and 6 h post infection directly into RLT buffer (Qiagen), the 
first stage of the RNA extraction procedure. FMDV RNA was 
quantified by a standard diagnostic real-time RT-PCR assay as 
described previously50,51 using amounts of RNA and cDNA 
which ensured that both the cDNA synthesis  and real time PCR 
were within the linear range of the assays. The numbers  of viral 
genomes in equal aliquots of RNA were determined by 
reference to a dilution series of RNA transcripts. 
Accession Numbers: Coordinates and structure factors have 
been deposited in  the Protein Data Bank with accession 
numbers 2wv4 and 2wv5.
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Supplementary Information
Supplementary Figure 1: Simulated annealing 
Fo-Fc omit maps contoured at  3σ for (a) 
3Cpro:VP1-2A (2.5 Å resolution)  and (b) 
3Cpro:VP1-2Am (2.7 Å resolution).
Supplementary Figure 2: Structural 
variation of co-crystal structures of 3Cpro-
peptide complexes. (a) Superposition of the 
two structures of the 3Cpro:VP1-2A  complex in 
the asymmetric unit  of the P212121 unit cell 
(Table 1). (b) Superposition of the four 
structures of the 3Cpro:VP1-2A complex in the 
asymmetric unit of the P21 unit cell (Table 1).
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Supplementary Figure 3: Mutagenic analysis of S1´ specificity.  SDS-PAGE analysis of 
polyprotein precursor digestion by FMDV 3Cpro mutants at (a) 0 min, (b) 10 min, (c) 20 min, (d) 30 
min, (e) 1 hrs, (f) 4 hrs and (g) 17 hrs. The polyprotein precursor used is depicted in Fig. 3a. Labels on 
the right hand side indicate the substrate (Sub.), the active 3Cpro (3Cact) and the primary cleavage 
products (Prod.)
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Supplementary Figure 4: Structural comparison of the S1´ binding pocket on FMDV and HRV 
3Cpro  (a) Complex of HRV 3Cpro  and a peptide-like inhibitor1 (PDB ID: 1cqq). The protein surface is 
coloured grey. The position of the cyclic glutamine side chain that occupies the P1 position in the 
inhibitor is labeled (P1-‘Q’).  (b) Structure of FMDV 3Cpro in the absence of a bound peptide2 (PDB 
ID 2j92). (c) Complex of FMDV 3Cpro  and the VP1-2A peptide (this work). The positions of the P1 
and P1´ residues are indicated.
Supplementary Figure 5: Activity of D84 mutants of FMDV 3Cpro in fluorescent peptide 
cleavage assays. (a) Cleavage activity  is observed as an increase in Arbitrary Fluorescent Units for a 
range of FRET4 substrate concentrations. (b) Same data as in panel (a) but rescaled on the vertical to 
show the difference between the D84E and D84A mutants. Note that at this scale, the first  data point 
for the wild-type activity is off the graph.
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Supplementary Movie 1: 
Morph animation showing the conformational changes in FMDV 3Cpro upon peptide binding. 
Viewpoint is the same as Figure 1e. Further description of key  features can be found in the audio 
commentary that accompanies the video. 
The video can be viewed online at:
http://www.bio.ph.ic.ac.uk/~scurry/FMDV-3c-pep-morph.html
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